Lypqozet Side Effects
Generic name: atorvastatin / ezetimibe
Medically reviewed by Drugs.com. Last updated on Nov 21, 2022.
Note: This document contains side effect information about atorvastatin / ezetimibe. Some dosage forms listed on this page may not apply to the brand name Lypqozet.
Applies to atorvastatin / ezetimibe: oral tablet.
Warning
You should not use this medicine if you have active liver disease or abnormal liver function tests.
Do not use atorvastatin and ezetimibe if you are pregnant or if you could become pregnant. Use effective birth control.
Do not breast-feed while using this medicine.
Get emergency medical help if you have any of these signs of an allergic reaction while taking atorvastatin / ezetimibe: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
In rare cases, atorvastatin can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have unexplained muscle pain, tenderness, or weakness especially if you also have fever, unusual tiredness, and dark colored urine.
Stop using this medicine and call your doctor at once if you have:
-
nausea, upper stomach pain, loss of appetite;
-
itching, unusual tiredness; or
-
dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Common side effects may include:
-
mild muscle pain;
-
stomach pain, diarrhea; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to atorvastatin / ezetimibe: oral tablet.
General
The more commonly reported adverse reactions have included increased ALT, increased AST, and musculoskeletal pain.[Ref]
Hepatic
Common (1% to 10%): ALT increased (5%), AST increased (4%)
Postmarketing reports: Hepatitis, cholelithiasis, cholecystitis, fatal and nonfatal hepatic failure[Ref]
Musculoskeletal
Common (1% to 10%): Musculoskeletal pain (3.8 to 4%), arthralgia (3 to 6.9%), pain in extremity (2.7 to 6%), myalgia (3.5%), muscle spasms (3%), muscle weakness (2%)
Postmarketing reports: Myopathy/rhabdomyolysis, necrotizing myopathy (rarely), injury, poisoning and procedural complication, tendon rupture, myositis[Ref]
Gastrointestinal
Common (1% to 10%): Diarrhea (4.1 to 6.8%), abdominal pain (3%), nausea (3 to 4%), dyspepsia (4.7%)[Ref]
Nervous system
Common (1% to 10%): Dizziness (2 to 6%), insomnia (3%), fatigue (2.4%)
Postmarketing reports: Headache, paraesthesia, peripheral neuropathy, amnesia, memory impairment, confusion, depression, dizziness[Ref]
Metabolic
Common (1% to 10%): Hyperkalemia (2%)[Ref]
Endocrine
Common (1% to 10%): Hot flushes (2%)[Ref]
Genitourinary
Common (1% to 10%): Urinary tract infection (5.7%)[Ref]
Hematologic
Postmarketing reports: Thrombocytopenia, elevated creatine phosphokinase[Ref]
Hypersensitivity
Postmarketing reports: Anaphylaxis, hypersensitivity reactions[Ref]
Immunologic
Common (1% to 10%): Influenza (2%)[Ref]
Respiratory
Common (1% to 10%): Coughing (2 to 3%), bronchitis (2%), sinusitis (2 to 2.8%), upper respiratory tract infection (4.3%), nasopharyngitis (up to 8.3%), pharyngolaryngeal pain (up to 2.3%)
Postmarketing reports: Interstitial lung disease[Ref]
Other
Postmarketing reports: Fatigue
Dermatologic
Postmarketing reports: Angioedema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rash, urticaria[Ref]
More about Lypqozet (atorvastatin / ezetimibe)
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Dosage information
- During pregnancy
- Drug class: antihyperlipidemic combinations
Patient resources
Other brands
Professional resources
Related treatment guides
References
1. Cerner Multum, Inc. Australian Product Information.
2. Product Information. Liptruzet (atorvastatin-ezetimibe). Merck & Co., Inc. 2013.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.